Vestcor Inc Acquires 9,600 Shares of Illumina, Inc. (NASDAQ:ILMN)

Vestcor Inc boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 300.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,793 shares of the life sciences company's stock after purchasing an additional 9,600 shares during the period. Vestcor Inc's holdings in Illumina were worth $1,668,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Empowered Funds LLC grew its holdings in Illumina by 1.7% during the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company's stock worth $516,000 after purchasing an additional 66 shares during the period. Caprock Group LLC boosted its stake in shares of Illumina by 3.0% during the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company's stock worth $376,000 after acquiring an additional 83 shares during the period. UMB Bank n.a. increased its holdings in shares of Illumina by 7.0% during the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company's stock worth $140,000 after acquiring an additional 88 shares during the last quarter. Integrated Advisors Network LLC raised its stake in Illumina by 2.0% in the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company's stock valued at $585,000 after acquiring an additional 90 shares during the period. Finally, Moors & Cabot Inc. lifted its holdings in Illumina by 1.7% during the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company's stock valued at $759,000 after purchasing an additional 95 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Down 0.8 %

Shares of Illumina stock traded down $1.21 during trading on Thursday, reaching $146.43. 1,192,524 shares of the company traded hands, compared to its average volume of 2,010,522. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The firm has a market capitalization of $23.22 billion, a PE ratio of -14.82 and a beta of 1.11. The company has a 50 day moving average price of $144.02 and a 200-day moving average price of $127.89. Illumina, Inc. has a 1-year low of $100.08 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business's quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.33 earnings per share. As a group, equities research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

ILMN has been the topic of several research analyst reports. Barclays increased their price objective on shares of Illumina from $135.00 to $145.00 and gave the company an "equal weight" rating in a research report on Tuesday, November 5th. Scotiabank reduced their price objective on Illumina from $176.00 to $164.00 and set a "sector outperform" rating for the company in a report on Thursday, August 15th. Stephens increased their target price on Illumina from $170.00 to $184.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 12th. UBS Group boosted their price target on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Finally, Citigroup lowered Illumina from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $190.00 to $165.00 in a report on Wednesday. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $162.86.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.